208 related articles for article (PubMed ID: 19775120)
1. PAMAM-RGD conjugates enhance siRNA delivery through a multicellular spheroid model of malignant glioma.
Waite CL; Roth CM
Bioconjug Chem; 2009 Oct; 20(10):1908-16. PubMed ID: 19775120
[TBL] [Abstract][Full Text] [Related]
2. Binding and transport of PAMAM-RGD in a tumor spheroid model: the effect of RGD targeting ligand density.
Waite CL; Roth CM
Biotechnol Bioeng; 2011 Dec; 108(12):2999-3008. PubMed ID: 21755497
[TBL] [Abstract][Full Text] [Related]
3. Acetylation of PAMAM dendrimers for cellular delivery of siRNA.
Waite CL; Sparks SM; Uhrich KE; Roth CM
BMC Biotechnol; 2009 Apr; 9():38. PubMed ID: 19389227
[TBL] [Abstract][Full Text] [Related]
4. The effects of an RGD-PAMAM dendrimer conjugate in 3D spheroid culture on cell proliferation, expression and aggregation.
Jiang LY; Lv B; Luo Y
Biomaterials; 2013 Apr; 34(11):2665-73. PubMed ID: 23340194
[TBL] [Abstract][Full Text] [Related]
5. Size and Surface Charge of Engineered Poly(amidoamine) Dendrimers Modulate Tumor Accumulation and Penetration: A Model Study Using Multicellular Tumor Spheroids.
Bugno J; Hsu HJ; Pearson RM; Noh H; Hong S
Mol Pharm; 2016 Jul; 13(7):2155-63. PubMed ID: 26828309
[TBL] [Abstract][Full Text] [Related]
6. Treatment of acute lung inflammation by pulmonary delivery of anti-TNF-α siRNA with PAMAM dendrimers in a murine model.
Bohr A; Tsapis N; Foged C; Andreana I; Yang M; Fattal E
Eur J Pharm Biopharm; 2020 Nov; 156():114-120. PubMed ID: 32798665
[TBL] [Abstract][Full Text] [Related]
7. Modulated cellular delivery of anti-VEGF siRNA (bevasiranib) by incorporating supramolecular assemblies of hydrophobically modified polyamidoamine dendrimer in stealth liposomes.
Golkar N; Samani SM; Tamaddon AM
Int J Pharm; 2016 Aug; 510(1):30-41. PubMed ID: 27291973
[TBL] [Abstract][Full Text] [Related]
8. Arginine-terminated generation 4 PAMAM dendrimer as an effective nanovector for functional siRNA delivery in vitro and in vivo.
Liu C; Liu X; Rocchi P; Qu F; Iovanna JL; Peng L
Bioconjug Chem; 2014 Mar; 25(3):521-32. PubMed ID: 24494983
[TBL] [Abstract][Full Text] [Related]
9. Arginine-glycine-aspartic acid-polyethylene glycol-polyamidoamine dendrimer conjugate improves liver-cell aggregation and function in 3-D spheroid culture.
Chen Z; Lian F; Wang X; Chen Y; Tang N
Int J Nanomedicine; 2016; 11():4247-59. PubMed ID: 27621619
[TBL] [Abstract][Full Text] [Related]
10. RGD-modified PEG-PAMAM-DOX conjugates: in vitro and in vivo studies for glioma.
Zhang L; Zhu S; Qian L; Pei Y; Qiu Y; Jiang Y
Eur J Pharm Biopharm; 2011 Oct; 79(2):232-40. PubMed ID: 21496485
[TBL] [Abstract][Full Text] [Related]
11. Co-delivery of curcumin and Bcl-2 siRNA by PAMAM dendrimers for enhancement of the therapeutic efficacy in HeLa cancer cells.
Ghaffari M; Dehghan G; Baradaran B; Zarebkohan A; Mansoori B; Soleymani J; Ezzati Nazhad Dolatabadi J; Hamblin MR
Colloids Surf B Biointerfaces; 2020 Apr; 188():110762. PubMed ID: 31911391
[TBL] [Abstract][Full Text] [Related]
12. Poly (amidoamine) (PAMAM) dendrimer mediated delivery of drug and pDNA/siRNA for cancer therapy.
Li J; Liang H; Liu J; Wang Z
Int J Pharm; 2018 Jul; 546(1-2):215-225. PubMed ID: 29787895
[TBL] [Abstract][Full Text] [Related]
13. Tat-BMPs-PAMAM conjugates enhance therapeutic effect of small interference RNA on U251 glioma cells in vitro and in vivo.
Han L; Zhang A; Wang H; Pu P; Jiang X; Kang C; Chang J
Hum Gene Ther; 2010 Apr; 21(4):417-26. PubMed ID: 19899955
[TBL] [Abstract][Full Text] [Related]
14. iRGD and TGN co-modified PAMAM for multi-targeted delivery of ATO to gliomas.
Shi X; Ma R; Lu Y; Cheng Y; Fan X; Zou J; Zheng H; Li F; Piao JG
Biochem Biophys Res Commun; 2020 Jun; 527(1):117-123. PubMed ID: 32446354
[TBL] [Abstract][Full Text] [Related]
15. RGD peptide-modified multifunctional dendrimer platform for drug encapsulation and targeted inhibition of cancer cells.
He X; Alves CS; Oliveira N; Rodrigues J; Zhu J; Bányai I; Tomás H; Shi X
Colloids Surf B Biointerfaces; 2015 Jan; 125():82-9. PubMed ID: 25437067
[TBL] [Abstract][Full Text] [Related]
16. Tumor penetrability and anti-angiogenesis using iRGD-mediated delivery of doxorubicin-polymer conjugates.
Wang K; Zhang X; Liu Y; Liu C; Jiang B; Jiang Y
Biomaterials; 2014 Oct; 35(30):8735-47. PubMed ID: 25023394
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of folate-PAMAM for the delivery of antisense oligonucleotides to rat C6 glioma cells in vitro and in vivo.
Kang C; Yuan X; Li F; Pu P; Yu S; Shen C; Zhang Z; Zhang Y
J Biomed Mater Res A; 2010 May; 93(2):585-94. PubMed ID: 19591231
[TBL] [Abstract][Full Text] [Related]
18. gamma-Glutamyl PAMAM dendrimer as versatile precursor for dendrimer-based targeting devices.
Uehara T; Ishii D; Uemura T; Suzuki H; Kanei T; Takagi K; Takama M; Murakami M; Akizawa H; Arano Y
Bioconjug Chem; 2010 Jan; 21(1):175-81. PubMed ID: 20000792
[TBL] [Abstract][Full Text] [Related]
19. A dual-targeting nanocarrier based on poly(amidoamine) dendrimers conjugated with transferrin and tamoxifen for treating brain gliomas.
Li Y; He H; Jia X; Lu WL; Lou J; Wei Y
Biomaterials; 2012 May; 33(15):3899-908. PubMed ID: 22364698
[TBL] [Abstract][Full Text] [Related]
20. Tumor angiogenic vasculature targeting with PAMAM dendrimer-RGD conjugates.
Shukla R; Thomas TP; Peters J; Kotlyar A; Myc A; Baker JR
Chem Commun (Camb); 2005 Dec; (46):5739-41. PubMed ID: 16307130
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
